曲美他嗪对慢性心力衰竭患者心功能和运动耐量的影响  

The effect of vasorel(trimetazidine) on cardiac function and execise capacity in patients with chronic heart failure

作　　者：庄海舟[1] 沈潞华[1] 郭春艳[1] 陈辉[1] 

机构地区：[1]首都医科大学附属北京友谊医院心血管中心,100050

出　　处：《北京医学》2005年第5期269-272,共4页Beijing Medical Journal

摘　　要：目的观察曲美他嗪(TMZ,商品名万爽力)对慢性心力衰竭(简称心衰)患者心功能和运动耐量的影响,分析其产生作用的可能机制。方法本实验为随机、开放、对照临床研究,选取39例因缺血性心肌病和扩张性心肌病而导致的慢性心衰患者(NYHAII、III级),随机分为对照组和TMZ组。用药观察期为3个月。全部入选患者在用药前和用药3个月时行超声心动图(用LVEF、EDD、ESD、FS、SV等指标)评价心脏收缩功能的改善情况,6min步行实验评价患者运动能力的改善情况。结果入选时两组资料有可比性。用药12周后,TMZ组的6min步行距离、FS、SV和EF值与对照组相比增高。两组患者血生化检查、血压、心率在组间和组内比较均无显著性差异。本研究无严重不良事件者。结论在常规心衰治疗的基础上加用曲美他嗪可以改善慢性心衰患者的心脏收缩功能,提高慢性心衰患者的运动耐量,并具有较好的耐受性。Objective To observe the effects of trimetazidine(vasorel) on cardiac function and exercise capacity in patients with CHF. And to explore the possible mechanism. Methods This is a random control, open clinical trial to evaluate the effect of vasorel in the patients with chronic heart failure. 39 patients with CHF (NYHA II or III) were involved. The reasons for CHF were ischemic cardiomyopathy and dilated cardiomyopathy. The patients were divided into two groups randomly: control group and the vasorel group. Patients were observed for 3 months. Echocardiography was performed prior and after the treatment to evaluate the improvement of cardiac function, The 6 minute walk test was used to evaluate the improvement of exercise capacity. Results The data of the two groups were comparable at enrolment. At 12 weeks, compare with the control group, the FS, SV, EF and 6 min walk distance test were significantly increased in group TMZ (P < 0.01). There was no significant difference in the blood biochemical tests and BP?HR between the two groups before treatment. There was no SDA found in our study. Conclusions Vasorel can improve cardiac function and exercise capacity in patients with chronic heart failure. It is well tolerated.

关 键 词：曲美他嗪 慢性心力衰竭 心功能 运动耐量 

分 类 号：R541.6[医药卫生—心血管疾病]